Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report, Stock No. 017–001–00473–1) referenced in the Introduction through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402–9325, telephone: (202) 512–1800.

Dated: July 1, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–18017 Filed 7–7–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

[Announcement 98043]

National Partnership for Human Immunodeficiency; Virus (HIV) Prevention; Notice of Availability of Funds for Fiscal Year 1998 Amendment

A notice announcing the availability of Fiscal Year 1998 funds for grants to support National Partnerships for Human Immunodeficiency Virus (HIV) Prevention Program was published in the **Federal Register** on June 3, 1998, [Vol. 63 FR No. 106]. The notice is amended as follows:

On page 30233, third column, under ''Eligible Applicants'', the first paragraph, line 12 should read: ''Tax-exempt status is determined by the Internal Revenue Service (IRS) Code, Section 501(c). Tax-exempt status may be proved by either providing a copy of the pages from the IRS' most recent list of 501 (c) tax-exempt organizations or a copy of the current IRS Determination Letter.''

On page 30238, second column, under ''Submission and Deadline'', the second paragraph should read: ''On or before August 7, 1998, submit the application to: Julia Valentine Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Announcement 98043, Centers for Disease Control and Prevention (CDC), Room 300, 255 East Paces Ferry Road, NE, M/S E15, Atlanta, GA 30305–2209.

All other information and requirements of the notice remain the same.

Dated: July 1, 1998.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–18015 Filed 7–7–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 98085]

Young People in Alternative Education Settings: Preventing HIV and Other Sexually Transmitted Diseases Notice of Availability of Fiscal Year 1998 Funds; Amendment

A notice announcing the availability of fiscal year (FY) 1998 funds for cooperative agreements for the prevention of human immunodeficiency virus (HIV), and other sexually transmitted diseases (STDs) among young people in alternative educational settings was published in the **Federal Register** on June 24, 1998, [Vol. 63 FR Number 121]. The notice is amended as follows:

On page 34432, third column, under ''Application Submission and Deadline'', the second paragraph should read: ''An original and two copies of the application PHS Form 5161–1 (Revised 5/96, OMB Number 0937–0189) must be submitted to Sharron P. Orum, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), Room 300, Mail Stop E–18, 255 East Paces Ferry Road, NE., Atlanta, GA 30305, on or before August 15, 1998.''

All other information and requirements of the notice remain the same.

Dated: July 01, 1998.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–18023 Filed 7–7–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Filing of Annual Reports

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that, as required by the Federal Advisory Committee Act, the agency has filed with the Library of Congress the annual reports of those FDA advisory committees that held closed meetings during fiscal year 1995, 1996, and 1997. FDA apologizes for the lateness in the filing of these reports due to circumstances beyond the agency's control.

ADDRESSES: Copies are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 301–443–1751.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4820.

SUPPLEMENTARY INFORMATION: Under section 13 of the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR 14.60(c), FDA has filed with the Library of Congress the annual reports for the following FDA advisory committees that held closed meetings during the period October 1, 1994, through September 30, 1995:

Center for Biologics Evaluation and Research:

Allergenic Products Advisory Committee,

Biological Response Modifiers Advisory Committee,

Blood Products Advisory Committee,

Vaccines and Related Biological Products Advisory Committee.

Center for Drug Evaluation and Research:

Anesthetic and Life Support Drugs Advisory Committee,

Anti-Infective Drugs Advisory Committee,

Antiviral Drugs Advisory Committee,

Arthritis Advisory Committee,

Drug Abuse Advisory Committee,

Endocrinologic and Metabolic Drugs Advisory Committee,

Generic Drugs Advisory Committee,

Medical Imaging Drugs Advisory Committee,

Nonprescription Drugs Advisory Committee,

Oncologic Drugs Advisory Committee.

Center for Devices and Radiological Health:

Medical Devices Advisory Committee (consisting of reports for the Anesthesiology and Respiratory Therapy Devices Panel; Circulatory System Devices Panel; Clinical Chemistry and Clinical Toxicology

Devices Panel (did not include a closed session); Dental Products Panel; Ear, Nose, and Throat Devices Panel; Gastroenterology and Urology Devices Panel; General and Plastic Surgery Devices Panel; General Hospital and Personal Use Devices Panel; Hematology and Pathology Devices Panel; Immunology Devices Panel; Microbiology Devices Panel; Neurological Devices Panel; Obstetrics and Gynecology Devices Panel; Ophthalmic Devices Panel; Orthopedic and Rehabilitation Devices Panel; and the Radiological Devices Panel).
National Center for Toxicological Research:

Science Advisory Board to the National Center for Toxicological Research.

FDA is also announcing the availability of annual reports for the following advisory committees during the period October 1, 1995, through September 30, 1996:
Center for Biologics Evaluation and Research:

Allergenic Products Advisory Committee,

Blood Products Advisory Committee,

Vaccines and Related Biological Products Advisory Committee.
Center for Drug Evaluation and Research:

Anesthetic and Life Support Drugs Advisory Committee,

Antiviral Drugs Advisory Committee,

Endocrinologic and Metabolic Drugs Advisory Committee,

Medical Imaging Drugs Advisory Committee,

Oncologic Drugs Advisory Committee,

Pulmonary-Allergy Drugs Advisory Committee.
Center for Devices and Radiological Health:

Medical Devices Advisory Committee (consisting of reports for the Anesthesiology and Respiratory Therapy Devices Panel; Circulatory System Devices Panel; Clinical Chemistry and Clinical Toxicology Devices Panel; Dental Products Panel; Ear, Nose, and Throat Devices Panel; Gastroenterology and Urology Devices Panel; General and Plastic Surgery Devices Panel; General Hospital and Personal Use Devices Panel; Hematology and Pathology Devices Panel; Immunology Devices Panel; Microbiology Devices Panel; Neurological Devices Panel; Obstetrics and Gynecology Devices Panel; Ophthalmic Devices Panel; Orthopedic and Rehabilitation Devices Panel; and the Radiological Devices Panel).
National Center for Toxicological Research:

Science Advisory Board to the National Center for Toxicological Research.

FDA is also announcing the availability of annual reports for the following advisory committees during the period October 1, 1996, through September 30, 1997:
Center for Biologics Evaluation and Research:

Allergenic Products Advisory Committee,

Biological Response Modifiers Advisory Committee,

Blood Products Advisory Committee,

Vaccines and Related Biological Products Advisory Committee.
Center for Drug Evaluation and Research:

Anesthetic and Life Support Drugs Advisory Committee,

Anti-Infective Drugs Advisory Committee,

Antiviral Drugs Advisory Committee,

Arthritis Advisory Committee,

Cardiovascular and Renal Drugs Advisory Committee,

Drug Abuse Advisory Committee,

Dermatologic and Ophthalmic Drugs Advisory Committee,

Endocrinologic and Metabolic Drugs Advisory Committee,

Nonprescription Drugs Advisory Committee.
Center for Devices and Radiological Health:

Medical Devices Advisory Committee (consisting of reports for the Anesthesiology and Respiratory Therapy Devices Panel; Circulatory System Devices Panel; Clinical Chemistry and Clinical Toxicology Devices Panel; Ear, Nose and Throat Devices Panel; Gastroenterology and Urology Devices Panel; General and Plastic Surgery Devices Panel; General Hospital and Personal Use Devices Panel; Hematology and Pathology Devices Panel; Immunology Devices Panel; Neurological Devices Panel; Obstetrics and Gynecology Devices Panel; Ophthalmic Devices Panel; Orthopedic and Rehabilitation Devices Panel; and Radiological Devices Panel).
National Center for Toxicological Research:

Science Advisory Board to the National Center for Toxicological Research.

Annual reports are available for public inspection at: (1) The Library of Congress, Madison Bldg., Newspaper and Current Periodical Reading Room, 101 Independence Ave. SE., rm. 133, Washington, DC; and (2) the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 29, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–18143 Filed 7–7–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0363]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on reporting and recordkeeping requirements for new animal drugs for investigational use.

DATES: Submit written comments on the collection of information by September 8, 1998.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party.